EMEA-002448-PIP01-18

Key facts

Active substance
PEGylated-fibroblast growth factor 21 (BMS-986036)
Therapeutic area
Gastroentology-Hepatology
Decision number
P/0336/2019
PIP number
EMEA-002448-PIP01-18
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of non-alcoholic steatohepatitis (NASH)
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Bristol-Myers Squibb International Corporation

Tel. +44 1895523740
E-mail: medical.information@bms.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating